During the three months period of 2-DG administration prior to tumor implantation, we observed a marginal decrease in the blood glucose level with a significant reduction in serum insulin concentration indicating increased insulin sensitivity (Fig 2E and 2F). This evidence concerns the gene INS and neoplasm.